Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Decreased by City Holding Co.

City Holding Co. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,742 shares of the medical research company’s stock after selling 573 shares during the period. City Holding Co.’s holdings in Thermo Fisher Scientific were worth $1,947,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 19.4% during the second quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company’s stock valued at $1,738,000 after buying an additional 510 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Thermo Fisher Scientific by 6.2% during the second quarter. Pacer Advisors Inc. now owns 28,900 shares of the medical research company’s stock valued at $15,982,000 after acquiring an additional 1,685 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Thermo Fisher Scientific by 5.5% in the second quarter. Thrivent Financial for Lutherans now owns 119,619 shares of the medical research company’s stock valued at $66,148,000 after buying an additional 6,185 shares during the period. Summit Trail Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 3.9% in the 2nd quarter. Summit Trail Advisors LLC now owns 4,164 shares of the medical research company’s stock worth $2,304,000 after purchasing an additional 157 shares in the last quarter. Finally, Westwood Holdings Group Inc. grew its position in Thermo Fisher Scientific by 80.5% in the second quarter. Westwood Holdings Group Inc. now owns 2,226 shares of the medical research company’s stock worth $1,231,000 after buying an additional 993 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock worth $25,954,465 in the last quarter. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $559.72 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company has a 50-day moving average of $529.96 and a 200-day moving average of $568.33. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a market capitalization of $214.09 billion, a price-to-earnings ratio of 35.09, a PEG ratio of 3.59 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business earned $5.69 earnings per share. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of analyst reports. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. TD Cowen raised their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Bank of America cut their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Finally, Barclays decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.